Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound ...
Snap (NYSE:SNAP) stock is down 7% on Thursday, heading toward $4.50 after opening at $4.90. That decline lands on the last trading session before Good Friday as the U.S. stock market is closed tomorrow. The move adds fresh pain to what has already been a brutal stretch for Snap’s loyal investors. Alarmingly, SNAP shares are ... Snap Falls 7% as Activist Pressure and Child Safety Scrutiny Compound an Already Brutal Year
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do ri...
Oil prices are surging today. WTI, the primary U.S. oil price benchmark, jumped more than 10% to over $110 a barrel. Meanwhile, Brent, the global benchmark price, rallied 6% to more than $107 per barrel. Crude prices are soaring following President Trump's address to the nation on Wednesday night, where he threatened to hit Iran "extremely hard." Here's a look at what energy investors should do right now. Image source: Getty Images. Continue reading
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic...
mbbirdy/E+ via Getty Images Canaccord Genuity launched its coverage of Tango Therapeutics ( TNGX ) with a Buy recommendation and a $30 target on Thursday, citing upside from three trial readouts the cancer drug developer is expected to announce this year. One of the readouts will follow a topline analysis from a Phase 1/2 trial designed to test the company’s lead asset, vopimetostat, in pancreatic cancer with MTAP deletions in combination with two RAS(ON) inhibitors developed by Revolution Medicines ( RVMD ). “Tango's strategy to combine with Revolution Medicines' KRAS agents in pancreatic cancer gives a meaningful head start vs. its competitors,” analyst John Newman wrote. “The combination will boost efficacy in MTAP-deleted and KRAS-mutated pancreatic cancer over Revolution Medicines’ KRAS-targeted agents alone,” he added. The analyst projects roughly $800M in peak U.S. sales from vopimetostat in MTAP-deleted non-small cell lung cancer, for which another readout from a Phase 1/2 monotherapy trial is anticipated in 2026. “We expect data here during 2026 with a focus on overall response rate and progression-free survival. Tango expects data to be quite mature, providing a meaningful readout for vopimetostat,” Newman argued. More on Tango Therapeutics Tango Therapeutics: I'm Not Buying Into Latest Rally, Despite PRMT5 Promise Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Tango Therapeutics, Inc. (TNGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Tango rises after Q4 results, clinical pact with Erasca Seeking Alpha’s Quant Rating on Tango Therapeutics
Munro/iStock via Getty Images The first quarter of 2026 was one of those eventful quarters that feels like two or three unfolded in the same time. While the U.S.-Iran War has been going on for over a month, there were several market narratives before that had made the market somewhat stagnant and fragile before the sell-off. There are several themes I'm still investing in despite their recent pain...
Munro/iStock via Getty Images The first quarter of 2026 was one of those eventful quarters that feels like two or three unfolded in the same time. While the U.S.-Iran War has been going on for over a month, there were several market narratives before that had made the market somewhat stagnant and fragile before the sell-off. There are several themes I'm still investing in despite their recent pain that I believe will rebound in Q2. We're already off the deepest lows, and while there are plenty of reasons to be worried or do a little hedging, I'm a believer that we hit a relative market bottom around late March, around the time I said that, “ It Is Time to Be Greedy .” Data by YCharts The SaaSpocalypse Will End Software-as-a-service ("SaaS") was one of the hot themes of the last decade and took a swift dump following the release of agentic coding tools by major frontier labs like OpenAI ( OPENAI ) and Anthropic ( ANTHRO ) in late January. This led to a massive decline in software services stocks, and to me publishing “ I'm Buying the Software Meltdown, ” where I wrote: The central flaw in the thesis against software stocks and the argument against AI eating software is that AI tools require humans to operate. Agents must be piloted, so to speak, and the firms that hire the best pilots ("prompt engineers"?) are likely to succeed even if the tools lower the barriers to entry. ...are we using our phones more now that there are more apps? Are the new apps gaining any actual market share or attention? The floor being lower for being an app developer means that there are more app developers, but it doesn't say that the long tail is paying off in that regard. The future of software in the AI world is unclear, as the ultimate potential of AI systems is still unclear. However, I don't believe that vibecoder entrepreneurs are going to replace the software sector. It doesn't make sense that AI coding tools will make software firms obsolete by allowing for in-house tools to be m...
The US president couldn’t give a single coherent reason for why this aggressive war of choice must still be prosecuted Donald Trump’s self-congratulatory speech on Iran on Wednesday night was as puzzling as it was divorced from reality. I had hoped he would declare victory and end the war. Some feared he might provide cover for a ground invasion. Instead, he told us in essence to be patient, that ...
The US president couldn’t give a single coherent reason for why this aggressive war of choice must still be prosecuted Donald Trump’s self-congratulatory speech on Iran on Wednesday night was as puzzling as it was divorced from reality. I had hoped he would declare victory and end the war. Some feared he might provide cover for a ground invasion. Instead, he told us in essence to be patient, that he is almost done, but he was utterly unclear about what more there is to accomplish. If there was ever a purpose to the war, it was to curtail Iran’s capacity to develop a nuclear weapon. Trump harped on that goal repeatedly in his speech, noting that he had long vowed that he “would never allow Iran to have a nuclear weapon”. But he didn’t mention that Iran has long agreed to eschew a nuclear weapon. If that is the only goal, this entire war has been pointless. Continue reading...
Generative artificial intelligence (AI) is undeniably the biggest tech megatrend in recent memory. And it has created plenty of millionaires and billionaires out of investors who bet big on the right companies at the right time. That said, not every generative AI stock has been a winner. SoundHound AI (NASDAQ: SOUN) has struggled to hold Wall Street's attention. And despite having a compelling bus...
Generative artificial intelligence (AI) is undeniably the biggest tech megatrend in recent memory. And it has created plenty of millionaires and billionaires out of investors who bet big on the right companies at the right time. That said, not every generative AI stock has been a winner. SoundHound AI (NASDAQ: SOUN) has struggled to hold Wall Street's attention. And despite having a compelling business strategy in the speech and voice AI niche, shares have fallen by a blistering 41% since the start of 2026. Let's explore the reasons why the stock is crashing and why it may be on the cusp of a turnaround over the next few years. Continue reading
Stocks on the U.S. markets opened lower on Thursday, April 2, 2026, before recovering to near breakeven by midday. Investors digested conflicting signals from the ongoing Iran conflict and a disappointing March delivery report from Tesla (NASDAQ: TSLA) . ^DJI data by https://ycharts.com ">YCharts Continue reading
Stocks on the U.S. markets opened lower on Thursday, April 2, 2026, before recovering to near breakeven by midday. Investors digested conflicting signals from the ongoing Iran conflict and a disappointing March delivery report from Tesla (NASDAQ: TSLA) . ^DJI data by https://ycharts.com ">YCharts Continue reading
Jennifer Johnston, senior vice president and director of research for municipal bonds at Franklin Templeton joins Scarlet Fu on "Bloomberg Markets." The US municipal market’s worst month in more than two years has cheapened the debt enough to lure some investors looking to add to their tax-exempt holdings. (Source: Bloomberg)
Jennifer Johnston, senior vice president and director of research for municipal bonds at Franklin Templeton joins Scarlet Fu on "Bloomberg Markets." The US municipal market’s worst month in more than two years has cheapened the debt enough to lure some investors looking to add to their tax-exempt holdings. (Source: Bloomberg)